relation: http://repositorio.uneatlantico.es/id/eprint/9218/ canonical: http://repositorio.uneatlantico.es/id/eprint/9218/ title: Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform creator: Martínez-Dubarbie, Francisco creator: Guerra-Ruiz, Armando creator: López-García, Sara creator: Lage, Carmen creator: Fernández-Matarrubia, Marta creator: Infante, Jon creator: Pozueta-Cantudo, Ana creator: García-Martínez, María creator: Corrales Pardo, Andrea creator: Bravo, María creator: López-Hoyos, Marcos creator: Irure-Ventura, Juan creator: Sánchez-Juan, Pascual creator: García-Unzueta, María Teresa creator: Rodríguez-Rodríguez, Eloy subject: Biomedicina subject: Psicología description: Background The arrival of new disease-modifying treatments for Alzheimer’s disease (AD) requires the identification of subjects at risk in a simple, inexpensive, and non-invasive way. With tools allowing an adequate screening, it would be possible to optimize the use of these treatments. Plasma markers of AD are very promising, but it is necessary to prove that alterations in their levels are related to alterations in gold standard markers such as cerebrospinal fluid or PET imaging. With this research, we want to evaluate the performance of plasma Aβ40, Aβ42, and p-tau181 to detect the pathological changes in CSF using the automated Lumipulse platform. Methods Both plasma and CSF Aβ40, Aβ42, and p-tau181 have been evaluated in a group of 208 cognitively unimpaired subjects with a 30.3% of ApoE4 carriers. We have correlated plasma and CSF values of each biomarker. Then, we have also assessed the differences in plasma marker values according to amyloid status (A − / +), AD status (considering AD + subjects to those A + plus Tau +), and ATN group defined by CSF. Finally, ROC curves have been performed, and the area under the curve has been measured using amyloid status and AD status as an outcome and different combinations of plasma markers as predictors. Results Aβ42, amyloid ratio, p-tau181, and p-tau181/Aβ42 ratio correlated significantly between plasma and CSF. For these markers, the levels were significantly different in the A + / − , AD + / − , and ATN groups. Amyloid ratio predicts amyloid and AD pathology in CSF with an AUC of 0.89. Conclusions Plasma biomarkers of AD using the automated Lumipulse platform show good diagnostic performance in detecting Alzheimer’s pathology in cognitively unimpaired subjects. date: 2023-10 type: Artículo type: PeerReviewed format: text language: en rights: cc_by_4 identifier: http://repositorio.uneatlantico.es/id/eprint/9218/1/s13195-023-01319-1.pdf identifier: Artículo Materias > Biomedicina Materias > Psicología Universidad Europea del Atlántico > Investigación > Producción Científica Abierto Inglés Background The arrival of new disease-modifying treatments for Alzheimer’s disease (AD) requires the identification of subjects at risk in a simple, inexpensive, and non-invasive way. With tools allowing an adequate screening, it would be possible to optimize the use of these treatments. Plasma markers of AD are very promising, but it is necessary to prove that alterations in their levels are related to alterations in gold standard markers such as cerebrospinal fluid or PET imaging. With this research, we want to evaluate the performance of plasma Aβ40, Aβ42, and p-tau181 to detect the pathological changes in CSF using the automated Lumipulse platform. Methods Both plasma and CSF Aβ40, Aβ42, and p-tau181 have been evaluated in a group of 208 cognitively unimpaired subjects with a 30.3% of ApoE4 carriers. We have correlated plasma and CSF values of each biomarker. Then, we have also assessed the differences in plasma marker values according to amyloid status (A − / +), AD status (considering AD + subjects to those A + plus Tau +), and ATN group defined by CSF. Finally, ROC curves have been performed, and the area under the curve has been measured using amyloid status and AD status as an outcome and different combinations of plasma markers as predictors. Results Aβ42, amyloid ratio, p-tau181, and p-tau181/Aβ42 ratio correlated significantly between plasma and CSF. For these markers, the levels were significantly different in the A + / − , AD + / − , and ATN groups. Amyloid ratio predicts amyloid and AD pathology in CSF with an AUC of 0.89. Conclusions Plasma biomarkers of AD using the automated Lumipulse platform show good diagnostic performance in detecting Alzheimer’s pathology in cognitively unimpaired subjects. metadata Martínez-Dubarbie, Francisco; Guerra-Ruiz, Armando; López-García, Sara; Lage, Carmen; Fernández-Matarrubia, Marta; Infante, Jon; Pozueta-Cantudo, Ana; García-Martínez, María; Corrales Pardo, Andrea; Bravo, María; López-Hoyos, Marcos; Irure-Ventura, Juan; Sánchez-Juan, Pascual; García-Unzueta, María Teresa y Rodríguez-Rodríguez, Eloy mail SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, andrea.corrales@uneatlantico.es, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR (2023) Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform. Alzheimer's Research & Therapy, 15 (1). ISSN 1758-9193 relation: http://doi.org/10.1186/s13195-023-01319-1 relation: doi:10.1186/s13195-023-01319-1 language: en